Market Place

Market Place

Market Place

Menu

Post Enquiry

Post Enquiry

PharmaCompass

Home

Market Place

Market Place

Search
All
API
FDF
Price
Services
Excipients
Enquiries

    Find

    • Active Pharmaceutical Ingredients Active Pharmaceutical Ingredients
    • Finished Drug Formulations Finished Drug Formulations
    • Price Price
    • Excipients Excipients
    • Services Services
    • Market Place Marketplace

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry
    FDA_Warning_Letters, Import_Alerts_&_EU_Non-Compliances_in_2019
    X

    Find Oncology Drugs in Phase I Clinical Development in UNITED KINGDOM

    A collaboration with SCORR Marketing

    Loading...

    All Data

    Filters Filter refresh
    ×
    FILTER DATA :
    News Type filter
      Company filter
        Product Type filter
          Deal Size filter
            Upfront Payment filter
              refresh

              Product Type

              Companies

              PsiOxus Therapeutics

              • Development Update

              Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

              UNITED KINGDOM United Kingdom

              Post An Enquiry Post An Enquiry

              Virtual Booth Virtual Booth

              WRIB

              Participation Not Confirmed

              Update your events

              PsiOxus Therapeutics Announces Clinical Trial with Third Cancer Gene Therapy Treatment

              Contact the Supplier

              Lead Product(s): NG-641

              Therapeutic Area: Oncology

              Highest Development Status: Phase I Product Type: Large molecule

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable March 05, 2020

              Details:

              This is the first time that a tumor-specific virus containing four different therapeutic transgenes has been administered to cancer patients.

              Mina Therapeutics

              • Development Update

              Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

              UNITED KINGDOM United Kingdom

              Post An Enquiry Post An Enquiry

              Virtual Booth Virtual Booth

              WRIB

              Participation Not Confirmed

              Update your events

              MiNA Therapeutics Announces Initiation of Phase I Clinical Study of MTL?CEBPA

              Contact the Supplier

              Lead Product(s): MTL-CEBPA,Pembrolizumab

              Therapeutic Area: Oncology

              Highest Development Status: Phase I Product Type: Large molecule

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable March 03, 2020

              Details:

              The study is designed to assess the safety, tolerability, pharmacology and clinical activity of MTL-CEBPA in combination with pembrolizumab in these patients.

              Mereo BioPharma Group

              • Deals

              Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

              UNITED KINGDOM United Kingdom

              Post An Enquiry Post An Enquiry

              Virtual Booth Virtual Booth

              WRIB

              Participation Not Confirmed

              Update your events

              Mereo BioPharma and Oncologie Enter into Global Licensing Agreement for Navicixizumab

              Contact the Supplier

              Lead Product(s): Navicixizumab

              Therapeutic Area: Oncology

              Highest Development Status: Phase I Product Type: Large molecule

              Partner/Sponsor/Collaborator: Oncologie

              Deal Size: $306.0 million Upfront Cash: $4.0 million

              Deal Type: Licensing Agreement January 13, 2020

              Details:

              Under the terms and conditions of the agreement, Oncologie receives exclusive global license to develop and commercialize navicixizumab.

              4D Pharma

              • Development Update

              Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

              UNITED KINGDOM United Kingdom

              Post An Enquiry Post An Enquiry

              Virtual Booth Virtual Booth

              WRIB

              Participation Not Confirmed

              Update your events

              Clinical Update - 4D Announce New Study of MRx0518 in Pancreatic Cancer

              Contact the Supplier

              Lead Product(s): MRx0518,Pembrolizumab

              Therapeutic Area: Oncology

              Highest Development Status: Phase I Product Type: Large molecule

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable January 06, 2020

              Details:

              The study is the second opened as part of a strategic collaboration to evaluate 4D's Live Biotherapeutic oncology pipeline across a range of cancer settings.

              PharmaCompass__DigitalAd